SCHEMBL1721096

SCHEMBL1721096

CCc1[nH]c(=O)c2cc(F)ccc2c1CN1CCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.43
TNKS O95271 2/20 0.42
KDM4E B2RXH2 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PARP2 Q9UGN5 1/20 0.39
KCNH2 Q12809 1/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 2/20 0.39
POLB P06746 2/20 0.39
HSD17B10 Q99714 2/20 0.38
HPGD P15428 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
CDK4 P11802 1/20 0.38
CCND1 P24385 1/20 0.38
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
MPO P05164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720655 0.87 MCL1 (0.41) PARP1TNKSALDH1A1DRD2DRD4
SCHEMBL1720072 0.85 ALDH1A1 (0.55) PARP1KDM4ESMN1; SMN2KMT2AALDH1A1
SCHEMBL1721010 0.85 KMT2A (0.48) PARP1TNKSKDM4ESMN1; SMN2PARP2
SCHEMBL10227704 0.84 PARP1 (0.43) PARP1KDM4EPARP2MPO
SCHEMBL1720570 0.83 CYP19A1 (0.42) PARP1KDM4ESMN1; SMN2ALDH1A1POLB
SCHEMBL1720059 0.83 CYP19A1 (0.42) PARP1KDM4ESMN1; SMN2ALDH1A1POLB
SCHEMBL1720056 0.83 CYP19A1 (0.42) PARP1KDM4ESMN1; SMN2ALDH1A1POLB
SCHEMBL1720552 0.83 CHRNA7 (0.46) PARP1KDM4EKMT2AALDH1A1MEN1
SCHEMBL10229094 0.80 PARP1 (0.52) PARP1KDM4EKMT2AALDH1A1MEN1
SCHEMBL1720556 0.79 PARP1 (0.43) PARP1KDM4EKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 PARP1 1/4885TNKS 127/4885KDM4E 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.